AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22949279 — intervention group
Group type: COMPARATOR
Intervention: Standard care (not explicitly mentioned)
Number of subjects: 73
Study 20067988 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose aprotinin (75,000 KIU/kg intra- and postoperatively)
Number of subjects: 399
Study 20067988 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose aprotinin (25,000 KIU/kg postoperatively)
Number of subjects: 399
Study 20067988 — intervention group
Group type: COMPARATOR
Intervention: High dose aprotinin (75,000 KIU/kg)
Number of subjects: 399
Study 20067988 — intervention group
Group type: COMPARATOR
Intervention: Low dose aprotinin (25,000 KIU/kg)
Number of subjects: 399
Study 17625124 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a and ribavirin for 16 weeks
Number of subjects: 1469
Study 17625124 — intervention group
Group type: COMPARATOR
Intervention: Peginterferon alfa-2a and ribavirin for 24 weeks
Number of subjects: 1469
Study 17625124 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a and ribavirin for 16 weeks (with pretreatment serum HCV RNA level of 400,000 IU/ml or less)
Number of subjects: 1469
Study 17625124 — intervention group
Group type: COMPARATOR
Intervention: Peginterferon alfa-2a and ribavirin for 24 weeks (with pretreatment serum HCV RNA level of 400,000 IU/ml or less)
Number of subjects: 1469
Study 17625124 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a and ribavirin for 16 weeks (with rapid virologic response)
Number of subjects: 1469
Study 17625124 — intervention group
Group type: COMPARATOR
Intervention: Peginterferon alfa-2a and ribavirin for 24 weeks (with rapid virologic response)
Number of subjects: 1469
Study 16206505 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA (branched-chain amino acid) granules at 12 g/day for 2 years
Number of subjects: 646
Study 16206505 — intervention group
Group type: COMPARATOR
Intervention: Diet therapy with defined daily food intake (1.0-1.4 g protein kg(‐1) day(‐1) including BCAA preparation and 25-35 kcal kg(‐1) day(‐1))
Number of subjects: 646
Study 11996327 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiduxosin (30 mg) under nonfasting conditions
Number of subjects: 14
Study 11996327 — intervention group
Group type: COMPARATOR
Intervention: Fiduxosin (30 mg) under fasting conditions
Number of subjects: 14
Study 10825862 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Total Toothpaste
Number of subjects: 63
Study 10825862 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 63
Study 8535198 — intervention group
Group type: EXPERIMENTAL
Intervention: Autoimmune phenomena (AP)
Number of subjects: 626
Study 8535198 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical autoimmune phenomena (CAP)
Number of subjects: 626
Study 8535198 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohaematological phenomena (IHP)
Number of subjects: 626
Study 2027271 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated calcium carbonate (3.6 g/d)
Number of subjects: 21
Study 2027271 — intervention group
Group type: COMPARATOR
Intervention: Gastric-coated calcium carbonate (3.1-3.6 g/d)
Number of subjects: 21
Study 2027271 — intervention group
Group type: COMPARATOR
Intervention: Aluminium hydroxide (2.9 g/d)
Number of subjects: 21
Study 2027271 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate (3.1-3.6 g/d)
Number of subjects: 21
Study 6955127 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive regimen including chairside education, dietary advice, oral hygiene instruction, and home consumption of a 1 mg fluoride tablet daily
Number of subjects: 242
Study 6955127 — intervention group
Group type: COMPARATOR
Intervention: Routine operative treatment needed to maintain dental fitness (Control)
Number of subjects: 242
Study 31438967 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses' assessment of AEs
Number of subjects: 334
Study 31438967 — intervention group
Group type: COMPARATOR
Intervention: Physicians' assessment of AEs
Number of subjects: 334
Study 31438967 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses' severity scores for symptomatic AEs
Number of subjects: 334
Study 31438967 — intervention group
Group type: EXPERIMENTAL
Intervention: Agreement on moderate or worse AEs
Number of subjects: 334
Study 28162930 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary stem cell therapy
Number of subjects: 10
Study 28162930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 25655011 — intervention group
Group type: EXPERIMENTAL
Intervention: Women after myocardial infarction
Number of subjects: 14503
Study 25655011 — intervention group
Group type: EXPERIMENTAL
Intervention: Women after myocardial infarction (echocardiographic study subset)
Number of subjects: 14503
Study 25655011 — intervention group
Group type: COMPARATOR
Intervention: Men after myocardial infarction
Number of subjects: 14503
Study 24176222 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin 750 mg twice daily
Number of subjects: 0
Study 24176222 — intervention group
Group type: COMPARATOR
Intervention: IV ceftriaxone 2 grams daily for four weeks
Number of subjects: 0
Study 21254841 — intervention group
Group type: EXPERIMENTAL
Intervention: Once weekly measurement and report online (Group A)
Number of subjects: 140
Study 21254841 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice weekly measurement and report online (Group B)
Number of subjects: 140
Study 21254841 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment with INR measurement in the lab every 4 weeks (Group C)
Number of subjects: 140
Study 19496683 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg), 10% caprylate/chromatography purified, 1 g/kg every 3 weeks
Number of subjects: 117
Study 19496683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 17537742 — intervention group
Group type: EXPERIMENTAL
Intervention: High sensitivity C-reactive protein (hs-CRP) measured at baseline
Number of subjects: 97
Study 14986784 — intervention group
Group type: EXPERIMENTAL
Intervention: Ignatia amara containing complex homeopathic remedies (IACCHR)
Number of subjects: 0
Study 14986784 — intervention group
Group type: COMPARATOR
Intervention: Standard pharmaceuticals
Number of subjects: 0
Study 11510064 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (1 microgram.kg‐1, i.v.) and propofol (1.5 mg.kg‐1.h‐1) during insertion of epidural catheters
Number of subjects: 16
Study 11510064 — intervention group
Group type: COMPARATOR
Intervention: No drug (control)
Number of subjects: 16
Study 9517606 — intervention group
Group type: EXPERIMENTAL
Intervention: budesonide
Number of subjects: 44
Study 9517606 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 44
Study 8112186 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,674 kJ/day (400 kcal)
Number of subjects: 93
Study 8112186 — intervention group
Group type: COMPARATOR
Intervention: 4,185 kJ/day (1,000 kcal)
Number of subjects: 93
Study 8112186 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,674 to 4,185 kJ (400 to 1,000 calories)
Number of subjects: 93
Study 8112186 — intervention group
Group type: EXPERIMENTAL
Intervention: 4,185 kJ (1,000 calories) throughout
Number of subjects: 93
Study 3280192 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 11
Study 3280192 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 11
Study 3280192 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Metoprolol + Nifedipine)
Number of subjects: 11
Study 30015681 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized adaptive quizzing
Number of subjects: 0
Study 30015681 — intervention group
Group type: COMPARATOR
Intervention: Preintervention cohort (no adaptive quizzing)
Number of subjects: 0
Study 27473562 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant sterol ester supplemented margarine (3g plant sterols per day)
Number of subjects: 16
Study 27473562 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 16
Study 25251767 — intervention group
Group type: EXPERIMENTAL
Intervention: Cysteamine 5% cream
Number of subjects: 50
Study 25251767 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 23759406 — intervention group
Group type: EXPERIMENTAL
Intervention: Skype condition (Internet‐based videoconferencing)
Number of subjects: 71
Study 23759406 — intervention group
Group type: COMPARATOR
Intervention: In-clinic condition
Number of subjects: 71
Study 21999299 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (5 g·day(‐1))
Number of subjects: 0
Study 21999299 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18433494 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led ART
Number of subjects: 12300
Study 18433494 — intervention group
Group type: COMPARATOR
Intervention: Doctor-led ART
Number of subjects: 12300
Study 16604827 — intervention group
Group type: EXPERIMENTAL
Intervention: High molecular weight hyaluronate, treated once weekly for 3 weeks
Number of subjects: 0
Study 16604827 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight hyaluronate, treated once weekly for 5 weeks
Number of subjects: 0
Study 16604827 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 14687510 — intervention group
Group type: EXPERIMENTAL
Intervention: nabumetone
Number of subjects: 1732
Study 14687510 — intervention group
Group type: EXPERIMENTAL
Intervention: meloxicam
Number of subjects: 1732
Study 14687510 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen
Number of subjects: 1732
Study 14687510 — intervention group
Group type: EXPERIMENTAL
Intervention: nimesulide
Number of subjects: 1732
Study 14687510 — intervention group
Group type: EXPERIMENTAL
Intervention: ibuprofen
Number of subjects: 1732
Study 14687510 — intervention group
Group type: EXPERIMENTAL
Intervention: diclofenac
Number of subjects: 1732
Study 14687510 — intervention group
Group type: EXPERIMENTAL
Intervention: oxaprozin
Number of subjects: 1732
Study 11018608 — intervention group
Group type: EXPERIMENTAL
Intervention: Deflazacort 30 mg daily (max 10 days) plus slow-release nifedipine 30 mg daily (max 4 weeks)
Number of subjects: 96
Study 11018608 — intervention group
Group type: COMPARATOR
Intervention: Wait-and-watch approach
Number of subjects: 96
Study 11018608 — intervention group
Group type: EXPERIMENTAL
Intervention: Deflazacort and nifedipine
Number of subjects: 96
Study 9028151 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (1200 mg/day)
Number of subjects: 53
Study 9028151 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 1513086 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous 1,25 dihydroxycholecalciferol (2 micrograms/m2)
Number of subjects: 11
Study 1513086 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (no intervention)
Number of subjects: 11
Study 6148339 — intervention group
Group type: EXPERIMENTAL
Intervention: prazepam (10 mg)
Number of subjects: 31
Study 6148339 — intervention group
Group type: EXPERIMENTAL
Intervention: clorazepate (7.5 mg)
Number of subjects: 31
Study 6148339 — intervention group
Group type: EXPERIMENTAL
Intervention: diazepam (5 mg)
Number of subjects: 31
Study 31464890 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuina therapy (once daily for 2 days)
Number of subjects: 0
Study 31464890 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuina therapy
Number of subjects: 0
Study 31464890 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care
Number of subjects: 0
Study 28112587 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereoscopic display
Number of subjects: 0
Study 28112587 — intervention group
Group type: COMPARATOR
Intervention: Non-stereoscopic display
Number of subjects: 0
Study 28112587 — intervention group
Group type: EXPERIMENTAL
Intervention: Video Game Experience (VGE)
Number of subjects: 0
Study 28112587 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow state
Number of subjects: 0
Study 24415509 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback from medical students
Number of subjects: 32
Study 24415509 — intervention group
Group type: COMPARATOR
Intervention: No feedback from medical students (Control)
Number of subjects: 32
Study 22955400 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic repair
Number of subjects: 60
Study 22955400 — intervention group
Group type: COMPARATOR
Intervention: Mini-open repair
Number of subjects: 60
Study 20926897 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospira filgrastim (5 μg/kg/day)
Number of subjects: 279
Study 20926897 — intervention group
Group type: COMPARATOR
Intervention: Amgen filgrastim (5 μg/kg/day)
Number of subjects: 279
Study 20926897 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospira filgrastim
Number of subjects: 279
Study 20926897 — intervention group
Group type: COMPARATOR
Intervention: Amgen filgrastim
Number of subjects: 279
Study 17685748 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 57
Study 17685748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 17685748 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent stimulant treatment
Number of subjects: 57
Study 15148348 — intervention group
Group type: EXPERIMENTAL
Intervention: STARBRIGHT CD-ROM program
Number of subjects: 47
Study 15148348 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 47
Study 11444452 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil 5 microg plus bupivacaine 1.25 mg (Group S)
Number of subjects: 40
Study 11444452 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal fentanyl 25 microg plus bupivacaine 1.25 mg (Group F)
Number of subjects: 40
Study 9589832 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesigyna (norethisterone enanthate, 50 mg, and estradiol valerate, 5 mg)
Number of subjects: 357
Study 9589832 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclofem (medroxyprogesterone acetate, 25 mg, and estradiol cypionate, 5 mg)
Number of subjects: 357
Study 9589832 — intervention group
Group type: EXPERIMENTAL
Intervention: Both preparations
Number of subjects: 357
Study 7977884 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical behavior therapy
Number of subjects: 26
Study 7977884 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 26
Study 2815168 — intervention group
Group type: EXPERIMENTAL
Intervention: Wet root canal instrumentation
Number of subjects: 0
Study 2815168 — intervention group
Group type: COMPARATOR
Intervention: Dry root canal instrumentation
Number of subjects: 0
Study 779926 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-mg nicotine chewing gum
Number of subjects: 43
Study 779926 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 43
Study 779926 — intervention group
Group type: COMPARATOR
Intervention: Smoking
Number of subjects: 43
Study 30625169 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype A1
Number of subjects: 383
Study 30625169 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype A2
Number of subjects: 383
Study 30625169 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype B1
Number of subjects: 383
Study 30625169 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype B2
Number of subjects: 383
Study 30625169 — intervention group
Group type: COMPARATOR
Intervention: 3M 1870
Number of subjects: 383
Study 30625169 — intervention group
Group type: COMPARATOR
Intervention: 3M 1860
Number of subjects: 383
Study 28315576 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild-compression knee high diabetic socks (18-25mmHg)
Number of subjects: 80
Study 28315576 — intervention group
Group type: COMPARATOR
Intervention: Non-compression knee high diabetic socks
Number of subjects: 80
Study 25901835 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab
Number of subjects: 881
Study 22487388 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 72
Study 22487388 — intervention group
Group type: COMPARATOR
Intervention: Control (Normal saline)
Number of subjects: 72
Study 22151988 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (1250 mg/m²) and Oxaliplatin (70 mg/m²) given on days 1 and 8 of a 21-day cycle
Number of subjects: 46
Study 22151988 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine and Oxaliplatin
Number of subjects: 46
Study 18648228 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (30 microg.kg.h)
Number of subjects: 27
Study 18648228 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (7.5 microg.kg.h)
Number of subjects: 27
Study 18648228 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 27
Study 17053267 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly visible CPP display
Number of subjects: 157
Study 17053267 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prominent CPP display)
Number of subjects: 157
Study 12916659 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromoendoscopy
Number of subjects: 0
Study 12916659 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnification endoscopy
Number of subjects: 0
Study 12916659 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromoendoscopy and magnification endoscopy
Number of subjects: 0
Study 12916659 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene blue
Number of subjects: 0
Study 10852255 — intervention group
Group type: EXPERIMENTAL
Intervention: RA‐1 (ayurvedic plant extract formulation)
Number of subjects: 182
Study 10852255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study 9663829 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentasa 1 g suppository once daily
Number of subjects: 50
Study 9663829 — intervention group
Group type: COMPARATOR
Intervention: Claversal 500 mg suppository b.d.
Number of subjects: 50
Study 8314414 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal glucose tolerance at baseline
Number of subjects: 637
Study 8314414 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance at baseline
Number of subjects: 637
Study 8314414 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes at baseline
Number of subjects: 637
Study 3782627 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose (6 ounces of juice)
Number of subjects: 8
Study 3782627 — intervention group
Group type: COMPARATOR
Intervention: Artificial sweetener (6 ounces of juice)
Number of subjects: 8
Study 31302205 — intervention group
Group type: EXPERIMENTAL
Intervention: DAA verification
Number of subjects: 52
Study 31302205 — intervention group
Group type: COMPARATOR
Intervention: Regular verification
Number of subjects: 52
Study 31302205 — intervention group
Group type: COMPARATOR
Intervention: Independent abstraction
Number of subjects: 52
Study 28429843 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimonabant 20 mg
Number of subjects: 2097
Study 28429843 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimonabant 5 mg
Number of subjects: 2097
Study 28429843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2097
Study 26503242 — intervention group
Group type: EXPERIMENTAL
Intervention: Altitude training (AT)
Number of subjects: 16
Study 26503242 — intervention group
Group type: COMPARATOR
Intervention: Control group (Cg)
Number of subjects: 16
Study 26503242 — intervention group
Group type: COMPARATOR
Intervention: Sea level training (SLT)
Number of subjects: 16
Study 25137195 — intervention group
Group type: EXPERIMENTAL
Intervention: Ballistic jump technique
Number of subjects: 11
Study 25137195 — intervention group
Group type: COMPARATOR
Intervention: Conventional concentric technique
Number of subjects: 11
Study 22105051 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusion training (4 weeks, low-intensity resistance training with blood-flow occlusion, 3 times per week)
Number of subjects: 32
Study 19170450 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional family therapy (MDFT)
Number of subjects: 83
Study 17762769 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based rehabilitation programme (20-week duration, 19 films, written material, internet dialogue)
Number of subjects: 60
Study 17762769 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list group (control)
Number of subjects: 60
Study 16150110 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin treatment
Number of subjects: 110
Study 16150110 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 12193522 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum alkaline phosphatase
Number of subjects: 108
Study 12193522 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone mineral content
Number of subjects: 108
Study 9619619 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical valves (St. Jude Medical, Omnicarbon)
Number of subjects: 213
Study 7659768 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (20 micrograms/kg per presentation) administered by nasal spray every 30 min for 2 h
Number of subjects: 18
Study 7659768 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.5 g/kg)
Number of subjects: 18
Study 7659768 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine plus alcohol
Number of subjects: 18
Study 7659768 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 2567580 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg cimetidine
Number of subjects: 24
Study 2567580 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg ranitidine
Number of subjects: 24
Study 2567580 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg cimetidine
Number of subjects: 24
Study 2567580 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 1019862 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinolytic therapy
Number of subjects: 17
Study 1019862 — intervention group
Group type: COMPARATOR
Intervention: Routine anticoagulant therapy
Number of subjects: 17
Study 30316888 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab 200 mg
Number of subjects: 58
Study 30316888 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 28655692 — intervention group
Group type: EXPERIMENTAL
Intervention: Linkus Syrup
Number of subjects: 147
Study 28655692 — intervention group
Group type: COMPARATOR
Intervention: Acefyllin Piperazine
Number of subjects: 147